They state that EXCEL will pile on deficits and continue to be profitless next year. I disagree because I feel that with recent approval of cabozantinib there should be an ever slow increase in revenue over subsequent quarters and into 2014. Not to mention further progression of their clinical trials which may culminate in further FDA approved indications for cabo,
Yup, I've come to realize the guys from Motley Fool are the biggest Fools around. They read from Cue Cards, also known as idiot cards which fits them perfectly, and their delivery is as smooth as sandpaper. Seeking Alpha guys at least seem to have thoughtful insight.